SWOG clinical trial number
SWOG-9037 (CALGB-9196)
Prediction of Recurrence and Survival in Node-Negative Breast Cancer Patients Using a Panel of Prognostic Factors: A Companion Protocol to SWOG-8897 (EST-2188, CALGB-8897, INT-0102)
Closed
Phase
Accrual
100%
Abbreviated Title
Prediction of Recurrence and Survival in Node-Negative Breast Cancer Patients Using a Panel of Prognostic Factors: A Companion Protocol to SWOG-8897 (EST-2188, CALGB-8897, INT-0102)
Activated
09/01/1990
Closed
05/15/1993
Research committees
Genitourinary Cancer
Other Clinical Trials
SWOG Clinical Trial Number
S2427
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26
A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase